Agios Pharmaceuticals

Agios’ is to discover and develop first-in-class therapies to treat cancer and rare genetic metabolic disorders. The company has a highly active R&D engine across several therapeutic areas, as well as multiple investigational medicines in clinical and preclinical development to address unmet needs for patients with cancer and rare genetic disorders. Agios was celebrated as a 2009 “Fierce 15” company by FierceBiotech and received $119M+ in funding as a private company.

In 2013, Agios launched an oversized IPO at $106M, trading on the NASDAQ under the ticker AGIO.


Company Profile

Agios Pharmaceuticals Logo

Flagship Partners:

  • Doug Cole, Managing Partner